 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ZL-1201 / ZAI Lab
Trial completion, Trial completion date, Metastases: A Trial of ZL-1201 in Subjects With Advanced Cancer (clinicaltrials.gov) - Aug 22, 2023
P1, N=37, Completed, Sponsor: Zai Lab (Shanghai) Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Jan 2023
- || ZL-1201 / ZAI Lab
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Trial of ZL-1201 in Subjects With Advanced Cancer (clinicaltrials.gov) - Aug 29, 2022
P1, N=37, Active, not recruiting, Sponsor: Zai Lab (Shanghai) Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Jan 2023 Recruiting --> Active, not recruiting | N=66 --> 37 | Trial primary completion date: Jan 2024 --> May 2022
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
The CD47-targeting antibody ZL-1201 enhances anti-tumor activity of standard of care therapeutic antibodies by promoting phagocytosis in hematologic and solid tumor models (Section 32) - Mar 9, 2022 - Abstract #AACR2022AACR_5237;
P1
This study indicates that ZL-1201 may combine with a broad range of SoC mAbs to enhance their clinical benefit across a variety of hematologic and solid tumor indications. ZL-1201 is under Ph1 clinical investigation (NCT04257617).
- ZL1201 / ZAI Lab
[VIRTUAL] ZL-1201, a differentiated CD47 therapeutic antibody with improved hematological safety profile () - Mar 13, 2021 - Abstract #AACR2021AACR_4099;
Thus, ZL-1201 treatment represents an effective CD47-targeting therapy with improved hematological safety consequences. A Ph1 dose escalation study to assess the safety of ZL-1201 is currently ongoing in patients with solid tumors, and future combination studies are planned for both hematologic and solid tumor indications.
- ||| ZL-1201 / ZAI Lab
Enrollment open, Metastases: A Trial of ZL-1201 in Subjects With Advanced Cancer (clinicaltrials.gov) - Jun 11, 2020
P1, N=65, Recruiting, Sponsor: Zai Lab (Shanghai) Co., Ltd.
A Ph1 dose escalation study to assess the safety of ZL-1201 is currently ongoing in patients with solid tumors, and future combination studies are planned for both hematologic and solid tumor indications. Not yet recruiting --> Recruiting
- ||| ZL-1201 / ZAI Lab
New P1 trial, Metastases: A Trial of ZL-1201 in Subjects With Advanced Cancer (clinicaltrials.gov) - Feb 6, 2020
P1, N=65, Not yet recruiting, Sponsor: Zai Lab (Shanghai) Co., Ltd.